Floatz logo

Ceritinib

CD30-Positive Neoplastic Cells Present

University of WashingtonSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the CD30-Positive Neoplastic Cells Present cohort.

Asset / SponsorPhaseRating
Brentuximab Vedotin
City of Hope Medical Center
Phase 1/2CCC
Cediranib
University of Washington
Phase 1/2CCC
cc-5013
City of Hope Medical Center
Phase 1CC
DEXAMETHASONE
City of Hope Medical Center
Phase 1CC

Same molecule, other indications

Ceritinib is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
pancreatic adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
Adenocarcinoma Lung Cancer; Squamous Cell Lung CarcinomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →